GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference
via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a
biotechnology company developing vaccines and immunotherapies
against infectious diseases and cancers, announced today that
Chairman, President, and CEO David Dodd will present at the H.C.
Wainwright Global Life Sciences Conference taking place March 9-10,
The presentation will be available for on-demand listening
beginning at 7:00 AM ET on Tuesday, March 9, 2021 and will be
available for 90 days. For those interested in viewing Mr.
Dodd’s presentation, conference registration can be
accessed here. Mr. Dodd will be available for virtual
one-on-one meetings with investors on March 9-10, and meeting
requests can be made on the conference website once an investor is
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing human vaccines against infectious
diseases and cancer using a novel patented Modified Vaccinia
Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On
this platform, MVA, a large virus capable of carrying several
vaccine antigens, expresses proteins that assemble into VLP
immunogens in the person receiving the vaccine. The production of
VLPs in the person being vaccinated can mimic virus production in a
natural infection, stimulating both the humoral and cellular arms
of the immune system to recognize, prevent, and control the target
infection. The MVA-VLP derived vaccines can elicit durable immune
responses in the host similar to a live-attenuated virus, while
providing the safety characteristics of a replication-defective
GeoVax’s current development programs are focused
on preventive vaccines against COVID-19, HIV, Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and
malaria, as well as therapeutic vaccines against multiple cancers.
The Company has designed a preventive HIV vaccine candidate to
fight against the subtype of HIV prevalent in the commercial
markets of the Americas, Western Europe, Japan, and Australia;
human clinical trials for this program are managed by the HIV
Vaccine Trials Network (HVTN) with the support of the National
Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of
two separate collaborative efforts to apply its innovative gene
therapy approach toward a functional cure for HIV.
GeoVax Labs, Inc.